Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
CC · NYSE · Diversified Chemicals
Chemours (CC) · oqro.io/stocks/CC · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$11.80−0.29 (−2.40%)
Close of Nov 19, 2026, vs Nov 18 · end-of-day
No open-market purchase by an insider of Chemours was filed in the last 90 days. The latest on record was on Aug 13, 2026.
Since 2015, Chemours insiders reported 47 open-market purchases and 78 sales on Forms 4 and 5, with purchases in 9 different years, most recently 2026.
No open-market sale by an insider of Chemours (CC) was filed with the SEC in the last 90 days.
No trade in Chemours (CC) was disclosed by a member of Congress in the last 12 months.
Chemours's next results are expected on Feb 17, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+10.3% (+$1.10) from Nov 19, 2025 to Nov 19, 2026 · adjusted daily closes
Adjusted close went from $10.70 on Nov 19, 2025 to $11.80 on Nov 19, 2026 (+10.3%). Disclosed in this range: 7 insider trades, 0 pre-arranged insider sales, 0 Congress trades, and 4 13F position changes for 4 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Diversified Chemicals company based in Wilmington, Delaware.
Last 12 months
+10.3%
Market value
$1.78B
S&P 500 +8.0% over the same dates. Prices adjusted for splits and dividends.
Short interest: 14.5M shares sold short (9.7% of shares outstanding), −2.1% vs the previous count, 6.8 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$5.81B
+0.4% vs the year before
Net income, fiscal 2025
−$386M
A loss for the year
Shares outstanding
151M
As of Oct 27, 2026
In fiscal 2025 the company spent $78M on dividends. Cash actually paid, from its cash-flow statement.
Last dividend: $0.0875 a share (quarterly), ex-date Nov 16, 2026, payable Dec 15, 2026. Calendar
Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Insider buying
6 insiders in a week, 2nd time since 2015Traded Aug 11 · filed 2 days later
Since the trade −20.3% · S&P 500 −7.1% · to Nov 19
Bought 47% below the 52-week high, RSI 37, 17% under its 200-day average, 46 points behind the S&P 500 over 3 months
The CEO of Chemours paid $51K out of pocket for Chemours shares. 6 other people at Chemours bought some too, in the same month.
Insider buying
7 insiders in a week, a first since 2015Traded Aug 12 · filed 1 day later
Since the trade −22.6% · S&P 500 −7.3% · to Nov 19
Bought 45% below the 52-week high, RSI 40, 15% under its 200-day average, 43 points behind the S&P 500 over 3 months
Chemours's See Remarks paid $30K out of pocket for Chemours shares. 6 other people at Chemours bought some too, in the same month.
Insider buying
5 insiders in a week, 3rd time since 2015Traded Aug 7 · filed 4 days later
Since the trade −25.1% · S&P 500 −7.4% · to Nov 19
Bought 44% below the 52-week high, RSI 40, 12% under its 200-day average, 35 points behind the S&P 500 over 3 months
A Chemours director paid $203K out of pocket for Chemours shares. 6 other people at Chemours bought some too, in the same month. Shares held went up 30% with this purchase.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Against the S&P 500 over the year
Since Nov 18, 2025, CC is up 8.0% and the index fund is up 8.5%: about the same. Traders call a stock that beats the index over a period a relative-strength leader.
How much CC moves
Beta 1.4 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 250 trading days (1 = in step with it).
On the public record for Chemours over the 12 months to Nov 21, 2026: 3 WARN notices.
Top officer leaving
“If a Participant (i) is involuntarily terminated without Cause (as defined in the Policy) or (ii) resigns for Good Reason (as defined in the Policy), the Company will provide the following payments and benefits to the Participant, subject to applicable tax withholding and certain exceptions as described in the Policy: Compensation Chief Executive Officer (“CEO”) Other Executive Officers and Employ”
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
No Schedule 13D or 13G filing on CC over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Insiders of Chemours reported 47 open-market purchases and 78 sales since 2015; purchases in 9 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $489K7×7 trades | — |
| 2025 | $301K4×4 trades | — |
| 2024 | — | $207K4×4 trades |
| 2023 | $515K2×2 trades | $1.45M6×6 trades |
| 2022 | — | $19.6M13×13 trades |
| 2021 | — | $12.3M17×17 trades |
| 2020 | $246K4×4 trades | $8.4M4×4 trades |
| 2019 | $2.16M10×10 trades | $3.57M6×6 trades |
| 2018 | $286K1×1 trade | $14.7M10×10 trades |
| 2017 | $98K1×1 trade | $7.22M17×17 trades |
| 2016 | $173K5×5 trades | — |
| 2015 | $1.38M13×13 trades | $1501×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
Latest annual report filed Feb 24, 2026, compared with the one filed Feb 18, 2025. Read the filing
We are subject to various legal proceedings, including, but not limited to, product liability, intellectual property, personal injury, commercial, contractual, employment, governmental, environmental and regulatory, anti-trust, and other such matters that arise in the ordinary course of business. In addition, we, by virtue of our status as a subsidiary of EID prior to the Separation, are subject to or required under the Separation-related agreements executed prior to the Separation to indemnify EID against various pending legal proceedings.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed Feb 24, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Revenue
$1.54B
+3.0% vs the same quarter a year earlier
Free cash flow, last 12 months
$211M
This quarter $98M, a year earlier $105M
Net debt
$3.13B
Debt $3.83B, cash $698M, at Sep 30, 2026
Backlog
$98M
Work contracted but not yet delivered, as the company reports it
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 2, 2026.
Revenue and earnings history, 13 fiscal yearsEarnings dates and the stock's moves
3 notices filed with state agencies, covering 75 workers in total. Employers must warn the state ahead of a plant closing or mass layoff at a site.
Official WARN lists from California, Texas, New York, Florida, Illinois and Washington only; notices filed in other states are not shown. Matched on the employer name as filed, so a notice filed under an unrelated subsidiary name can be missing. Dates are the notice date (Washington: the date the state received it).
0 certified in FY2026 Q3, vs 1 a year earlier.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Last results
Nov 2, 2026
Within the 30 days after it, until Dec 2, 2026
Next results, expected
Feb 17, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
77%
36 of 47 insider purchases since 2015 came within 30 days after a results announcement
From Chemours's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Chemours's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
The three months Jul 1, 2026 to Sep 30, 2026, compared with the same quarter a year earlier, from the quarterly report filed Nov 5, 2026. Quarterly reports are not audited. Read the filing
+11% on the same quarter a year earlier ($612M)
−8.9% on the same quarter a year earlier ($560M)
+8.4% on the same quarter a year earlier ($311M)
+8.3% on the same quarter a year earlier ($12M)
The company also reports Segment Total ($1.53B), which group lines above and are not added again.
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Feb 24, 2026. Read the filing
−5.6% on the year before ($2.57B)
+13% on the year before ($1.83B)
−4.8% on the year before ($1.33B)
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 21,000 words.
We are a leading, global provider of performance chemicals that are key inputs in end-products and processes in a variety of industries. We deliver customized solutions with a wide range of industrial and specialty chemical products for markets, including refrigeration and air conditioning, paints and coatings, plastics, transportation, semiconductor and consumer electronics, general industrial, and oil and gas. Our principal products include refrigerants, titanium dioxide ("TiO2") pigment and industrial fluoropolymer resins. We manage and report our operating results through three principal reportable segments: Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials.
Source: SEC EDGAR, Form 10-K filed Feb 24, 2026 and Form 10-Q filed Nov 5, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
−7.4% on the year before ($54M)
The company also reports Segment Total ($5.76B), which group lines above and are not added again.
+2.5% on the year before ($2.59B)
−10% on the year before ($1.39B)
+2.2% on the year before ($1.14B)
+12% on the year before ($669M)
And 26 more headings in the filing.
Off-exchange trading: 38.2% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (24.2% on ATS, 14.0% with other brokers), close to its 26-week average of 38.8%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: UBS ATS (14.9%), INTELLIGENT CROSS LLC (13.7%), MS TRAJECTORY CROSS (ATS-1) (8.2%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.